RELiZORB— 510(k) K191379

Substantially Equivalent

Alcresta Therapeutics, Inc.

FDA 510(k) clearance K191379 for RELiZORB, Substantially Equivalent on 2019-12-04. Applicant: Alcresta Therapeutics, Inc..

Clearance details

Applicant: Alcresta Therapeutics, Inc.
Product code: Code PLQ
Advisory panel: Gastroenterology, Urology
Date received: 2019-05-23
Decision date: 2019-12-04
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Newton, MA, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.